Standout Papers

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors 2021 2026 2022 2024299
  1. FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors (2021)
    Leigh Marcus, Lola A. Fashoyin‐Aje et al. Clinical Cancer Research
  2. FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC (2021)
    Erica C. Nakajima, Nicole Drezner et al. Clinical Cancer Research
  3. Trends in the approval of cancer therapies by the FDA in the twenty-first century (2023)
    Emma Scott, Andrea Baines et al. Nature Reviews Drug Discovery

Immediate Impact

2 by Nobel laureates 7 from Science/Nature 59 standout
Sub-graph 1 of 22

Citing Papers

The B7:CD28 family and friends: Unraveling coinhibitory interactions
2024 Standout
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression
2024 Standout

Works of Julia A. Beaver being referenced

FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer
2021
FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer
2020
and 1 more

Author Peers

Author Last Decade Papers Cites
Julia A. Beaver 2572 1414 1014 1069 129 4.5k
Shenghui Tang 2809 1763 817 1156 115 5.1k
Kirsten B. Goldberg 2625 1239 687 949 66 4.3k
Dario Trapani 2120 1140 929 879 191 4.0k
Gideon M. Blumenthal 3884 2494 1304 2344 119 7.2k
Gilberto Lopes 2141 1414 584 520 210 3.5k
Sophie Postel‐Vinay 3110 1651 913 2143 115 5.5k
Robert Justice 2481 1657 856 2757 61 6.3k
Bruce J. Giantonio 3309 1541 743 1266 123 4.9k
Erica L. Mayer 2526 966 1181 1359 138 4.6k
David W. Cescon 2764 1097 1348 1690 166 5.3k

All Works

Loading papers...

Rankless by CCL
2026